ARYX (ARYx Therapeutics) Ending Cash Position: $2.95 Mil (As of Sep. 2010)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ARYx Therapeutics Ending Cash Position?

ARYx Therapeutics ARYX -99.80% Ending Cash Position is $2.95 Mil as of Sep. 2010.

ARYx Therapeutics's Ending Cash Position for the quarter that ended in Sep. 2010 was $2.95 Mil.

ARYx Therapeutics's quarterly Ending Cash Position declined from Mar. 2010 ($6.30 Mil) to Jun. 2010 ($1.40 Mil) but then increased from Jun. 2010 ($1.40 Mil) to Sep. 2010 ($2.95 Mil).

ARYx Therapeutics's annual Ending Cash Position declined from Dec. 2007 ($55.48 Mil) to Dec. 2008 ($36.00 Mil) and declined from Dec. 2008 ($36.00 Mil) to Dec. 2009 ($7.41 Mil).

ARYx Therapeutics Ending Cash Position Related Terms

ARYx Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for ARYx Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ARYx Therapeutics Ending Cash Position Chart

ARYx Therapeutics Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09
Ending Cash Position
Get a 7-Day Free Trial 12.46 18.66 55.48 36.00 7.41

ARYx Therapeutics Quarterly Data
Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.85 7.41 6.30 1.40 2.95

ARYx Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ARYx Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2009 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=35.999+-28.59
=7.41

ARYx Therapeutics's Ending Cash Position for the quarter that ended in Sep. 2010 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.404+1.55
=2.95

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $2.95 Mil mean?
ARYx Therapeutics (ARYX) has a Ending Cash Position of $2.95 Mil as of Sep. 2010. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ARYx Therapeutics and its competitors.
Is ARYx Therapeutics' Ending Cash Position too high?
ARYx Therapeutics' current Ending Cash Position is $2.95 Mil.
How does ARYx Therapeutics' Ending Cash Position compare to YBAO and HPMM?
ARYx Therapeutics' Ending Cash Position of $2.95 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ARYx Therapeutics and its competitors. ARYx Therapeutics's current Ending Cash Position is $2.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARYx Therapeutics stock overvalued right now?
ARYx Therapeutics (ARYX) has a current Ending Cash Position of $2.95 Mil. The current Ending Cash Position is $2.95 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For ARYx Therapeutics (ARYX), the current Ending Cash Position is $2.95 Mil as of Sep. 2010. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ARYx Therapeutics Business Description

Address 6300 Dumbarton Circle, Fremont, CA, USA, 94555
ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.